XFOR (X4 Pharmaceuticals) Net Margin %: -747.45% (As of Mar. 2026)

What is X4 Pharmaceuticals Net Margin %?

X4 Pharmaceuticals XFOR +0.61% 29 Net Margin % is -747.45% as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review. Among 947 Biotechnology companies, X4 Pharmaceuticals ranks worse than 79.83% on this metric.

Net margin is calculated as Net Income divided by its Revenue. X4 Pharmaceuticals's Net Income for the three months ended in Mar. 2026 was $-20.24 Mil. X4 Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $2.71 Mil. Therefore, X4 Pharmaceuticals's net margin for the quarter that ended in Mar. 2026 was -747.45%.

The historical rank and industry rank for X4 Pharmaceuticals's Net Margin % or its related term are showing as below:

XFOR' s Net Margin % Range Over the Past 10 Years
Min: -2071.03 Med: -1464.61 Max: -225.55
Current: -1106.3

XFOR's Net Margin % is ranked worse than
79.83% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs XFOR: -1106.30

X4 Pharmaceuticals (NAS:XFOR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

X4 Pharmaceuticals Net Margin % Related Terms

X4 Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Net Margin % Chart

X4 Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

0.00

-1,464.61

-225.55

X4 Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.98	-1,304.66	-1,689.24	-931.66	-747.45

XFOR vs ZURA, LYEL, LXEO: Net Margin % Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Net Margin % falls into.

Save Embed

29GF Score

X4 Pharmaceuticals Inc XFOR

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

X4 Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

X4 Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-79.199	/	35.113
	=	-225.55 %

X4 Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-20.241	/	2.708
	=	-747.45 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -747.45% mean?

X4 Pharmaceuticals (XFOR) has a Net Margin % of -747.45% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on X4 Pharmaceuticals and its competitors. According to the industry distribution chart, X4 Pharmaceuticals ranks #756 out of 947 companies in the Biotechnology industry, placing it in the top 79.8%.

Is X4 Pharmaceuticals' Net Margin % too high?

X4 Pharmaceuticals' current Net Margin % is -747.45%. Based on the distribution chart, X4 Pharmaceuticals ranks #756 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does X4 Pharmaceuticals' Net Margin % compare to ZURA and LYEL?

According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #756 out of 947 companies for Net Margin %. This places X4 Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Net Margin % is -747.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is X4 Pharmaceuticals stock overvalued right now?

X4 Pharmaceuticals (XFOR) has a current Net Margin % of -747.45%. The current Net Margin % is -747.45%. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Net Margin % is -747.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ZURA LYEL LXEO CYDY BNTC OABI FBRX VNDA ARTV CMPX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134

Website https://www.x4pharma.com

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

29GF Score

Get the complete analysis for XFOR

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12

Price

View XFOR Analysis

See Net Margin % data for all stocks →